We hypothesized that obesity will increase liver steatosis and DHEA treatment will protect against liver steatosis by reducing body weight gain and modulating serum IGF-1 and IGFBP-3 levels in breast cancer model. The gene discussed is IGF1; the disease is obesity due to melanocortin 4 receptor deficiency.